Policies around transitioning to biosimilars in Europe, the U.S. and Canada
Sixty per cent of all prescriptions in Canada are paid for by employer-provided drug plans and some have life-time limits for biologic reimbursement. However, transitioning to a biosimilar…
- By: Cassandra Williamson-Hopp
- October 18, 2019 November 12, 2020
- 08:45